Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens

Journal of Infectious Diseases

Volumn 214, Issue 3, 2016, Pages 390-398

  Buckner, Clarisa M ^a   Kardava, Lela ^a   Zhang, Xiaozhen ^a   Gittens, Kathleen ^b   Shawn Justement, J ^a   Kovacs, Colin ^f,g   McDermott, Adrian B ^a   Li, Yuxing ^c   Sajadi, Mohammad M ^d,e   Chun, Tae Wook ^a   Fauci, Anthony S ^a   Moir, Susan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

^e BALTIMORE VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Maple Leaf Medical   (Canada)

Author keywords

B cells; elite controllers; HIV; humoral immunity; viremia

Indexed keywords

ANTIRETROVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; TETANUS TOXIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MALE; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIREMIA; VIRUS REPLICATION; B LYMPHOCYTE; BLOOD; COHORT ANALYSIS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HIV SURVIVOR; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 84981167153     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw163     Document Type: Article

References (50)

1. Amu S, Ruffin N, Rethi B, Chiodi F. Impairment of B-cell functions during HIV-1 infection. AIDS 2013; 27:2323-34.
2. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev 2013; 254:207-24.
3. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of anti-retroviral therapy. Blood 2010; 116:5571-9.
4. Buckner CM, Moir S, Ho J, et al. Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J Virol 2013; 87:5800-11.
5. Kardava L, Moir S, Shah N, et al. Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Invest 2014; 124:3252-62.
6. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 2011; 6:163-8.
7. Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol 2015; 16:563-70.
8. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 2013; 13:487-98.
9. Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis 2008; 47:102-4.
10. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-9.
11. Chen H, Ndhlovu ZM, Liu D, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol 2012; 13:691-700.
12. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6: e1000917.
13. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-21.
14. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
15. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-12.
16. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 2014; 209:931-9.
17. Hunt PW, Landay AL, Sinclair E, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 2011; 6:e15924.
18. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
19. Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84:1631-6.
20. Sajadi MM, Guan Y, DeVico AL, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 2011; 57:9-15.
21. Ackerman ME, Mikhailova A, Brown EP, et al. Polyfunctional HIV-Specific antibody responses are associated with spontaneous HIV control. PLoS Pathog 2016; 12:e1005315.
22. Pensieroso S, Galli L, Nozza S, et al. B-cell subset alterations and correlated factors in HIV-1 infection. AIDS 2013; 27:1209-17.
23. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984-90.
24. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010; 84:7018-28.
25. Mens H, Kearney M, Wiegand A, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84:12971-81.
26. Chun TW, Shawn Justement J, Murray D, et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis 2013; 208:1443-7.
27. Sajadi MM, Constantine NT, Mann DL, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 2009; 50:403-8.
28. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007; 21:517-9.
29. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci USA 2006; 103:2262-7.
30. Meffre E, Louie A, Bannock J, et al. Maturational characteristics of HIV-specific antibodies in viremic individuals. JCI Insight 2016; 1:e84610.
31. Bussmann BM, Reiche S, Bieniek B, Krznaric I, Ackermann F, Jassoy C. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. Virology 2010; 397:7-13.
32. Lavinder JJ, Wine Y, Giesecke C, et al. Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci USA 2014; 111:2259-64.
33. Cortes FH, Passaes CP, Bello G, et al. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J Acquir Immune Defic Syndr 2015; 68:377-85.
34. Cockerham LR, Hatano H. Elite control of HIV: is this the right model for a functional cure? Trends Microbiol 2015; 23:71-5.
35. Andrabi R, Makhdoomi MA, Kumar R, et al. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. J Clin Immunol 2014; 34:504-13.
36. Gach JS, Achenbach CJ, Chromikova V, et al. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive anti-retroviral therapy (ART): a cross-sectional study. PLoS One 2014; 9:e85371.
37. Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol 2011; 85:5804-13.
38. Cubas R, van Grevenynghe J, Wills S, et al. Reversible reprogramming of circulating memory T Follicular helper cell function during chronic HIV infection. J Immunol 2015; 195:5625-36.
39. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008; 197:572-9.
40. Ferreira CB, Merino-Mansilla A, Llano A, et al. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations. J Virol 2013; 87:12227-36.
41. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-78.
42. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antire-troviral therapy. J Virol 2009; 83:329-35.
43. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007; 21:1043-5.
44. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691.
45. Julg B, Pereyra F, Buzon MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 2010; 51:233-8.
46. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
47. Mahalanabis M, Jayaraman P, Miura T, et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 2009; 83:662-72.
48. van Gils MJ, Bunnik EM, Burger JA, et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol 2010; 84:3576-85.
49. Ackerman ME, Dugast AS, Alter G. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med 2012; 63:113-30.
50. Martin-Gayo E, Buzon MJ, Ouyang Z, et al. Potent cell-Intrinsic immune responses in dendritic cells facilitate HIV-1-Specific T Cell immunity in HIV-1 elite controllers. PLoS Pathog 2015; 11:e1004930.